Biologic drug products are not new – their development began decades ago; the first monoclonal antibody was commercialized in 1986.^[1] With the increasing availability of genetic information, and better understanding of subcellular cascades and disease processes, the number of biologic drug products available has increased substantially in response to an exponential growth in targets. ^[2]